Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMIT: Dacarbazine Followed by Immunotherapy Re-challenge in Melanoma
NCT04225390Phase 2Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jan 2020
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacarbazine in melanoma, sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Rate of participants with Complete Response, Partial Response, Stable Disease or Progressive Disease at 14 weeks. Started Jan 2020; status: completed.
02
Drugs
dacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04225390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225390.